HUP0003885A2 - Készítmény pangásos szívelégtelenség kezelésére - Google Patents
Készítmény pangásos szívelégtelenség kezeléséreInfo
- Publication number
- HUP0003885A2 HUP0003885A2 HU0003885A HUP0003885A HUP0003885A2 HU P0003885 A2 HUP0003885 A2 HU P0003885A2 HU 0003885 A HU0003885 A HU 0003885A HU P0003885 A HUP0003885 A HU P0003885A HU P0003885 A2 HUP0003885 A2 HU P0003885A2
- Authority
- HU
- Hungary
- Prior art keywords
- formulation
- heart failure
- congestive heart
- treating congestive
- active ingredient
- Prior art date
Links
- 206010007559 Cardiac failure congestive Diseases 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65946396A | 1996-06-06 | 1996-06-06 | |
| PCT/US1997/009914 WO1997046241A1 (en) | 1996-06-06 | 1997-06-05 | Formulation and method for treating congestive heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0003885A2 true HUP0003885A2 (hu) | 2001-04-28 |
Family
ID=24645503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0003885A HUP0003885A2 (hu) | 1996-06-06 | 1997-06-05 | Készítmény pangásos szívelégtelenség kezelésére |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0914128A1 (de) |
| JP (1) | JP2000511906A (de) |
| KR (1) | KR20000016406A (de) |
| CN (1) | CN1226166A (de) |
| AU (1) | AU3233197A (de) |
| BR (1) | BR9709546A (de) |
| CA (1) | CA2256720A1 (de) |
| CZ (1) | CZ397698A3 (de) |
| EA (1) | EA199900006A1 (de) |
| HU (1) | HUP0003885A2 (de) |
| IL (1) | IL126966A0 (de) |
| NO (1) | NO985695L (de) |
| PL (1) | PL330637A1 (de) |
| TR (1) | TR199802496T2 (de) |
| WO (1) | WO1997046241A1 (de) |
| YU (1) | YU55998A (de) |
| ZA (1) | ZA974978B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19815411A1 (de) * | 1998-04-06 | 1999-10-07 | Solvay Pharm Gmbh | Thermogenese stimulierend wirksame Arzneimittel |
| AU2727400A (en) * | 1999-01-29 | 2000-08-18 | Eli Lilly And Company | Moxonidine salts |
| CN1166363C (zh) | 1999-02-01 | 2004-09-15 | 索尔瓦药物有限公司 | 莫索尼定在制备治疗心肌梗塞造成的心肌损伤的药物中的应用 |
| DE602006018139D1 (de) * | 2006-08-31 | 2010-12-23 | Chemagis Ltd | Verwendung der Monoxidinssalze zur Reinigung von Monoxidin |
| KR100812287B1 (ko) * | 2007-01-03 | 2008-03-13 | 주식회사 챠콜코리아 | 내면에 반사층을 갖는 신호등 갓 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
| DE3617158C2 (de) * | 1986-05-22 | 1994-10-06 | Lohmann Therapie Syst Lts | Transdermales Arzneimittel |
| DE3729299A1 (de) * | 1987-09-02 | 1989-03-23 | Beiersdorf Ag | Transdermales therapeutisches system |
| DE3904795C2 (de) * | 1989-02-17 | 2000-10-12 | Lilly Pharma Produktion Gmbh & | Pharmazeutisches Präparat und dessen Verwendung |
| DE4325491A1 (de) * | 1993-07-29 | 1995-02-02 | Boehringer Ingelheim Kg | Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels |
| DE4423177A1 (de) * | 1994-07-01 | 1996-01-04 | Kali Chemie Pharma Gmbh | Antihyperglykämisch wirksame Arzneimittel |
| CA2182851A1 (en) * | 1995-08-15 | 1997-02-16 | August Masaru Watanabe | Method for treating substance abuse withdrawal |
-
1997
- 1997-06-05 PL PL97330637A patent/PL330637A1/xx unknown
- 1997-06-05 HU HU0003885A patent/HUP0003885A2/hu unknown
- 1997-06-05 CN CN97196854A patent/CN1226166A/zh active Pending
- 1997-06-05 WO PCT/US1997/009914 patent/WO1997046241A1/en not_active Application Discontinuation
- 1997-06-05 IL IL12696697A patent/IL126966A0/xx unknown
- 1997-06-05 JP JP10500901A patent/JP2000511906A/ja active Pending
- 1997-06-05 KR KR1019980709980A patent/KR20000016406A/ko not_active Application Discontinuation
- 1997-06-05 EP EP97928011A patent/EP0914128A1/de not_active Withdrawn
- 1997-06-05 ZA ZA974978A patent/ZA974978B/xx unknown
- 1997-06-05 CA CA002256720A patent/CA2256720A1/en not_active Abandoned
- 1997-06-05 TR TR1998/02496T patent/TR199802496T2/xx unknown
- 1997-06-05 AU AU32331/97A patent/AU3233197A/en not_active Abandoned
- 1997-06-05 BR BR9709546A patent/BR9709546A/pt not_active Application Discontinuation
- 1997-06-05 CZ CZ983976A patent/CZ397698A3/cs unknown
-
1998
- 1998-12-04 NO NO985695A patent/NO985695L/no not_active Application Discontinuation
- 1998-12-04 YU YU55998A patent/YU55998A/sr unknown
-
1999
- 1999-01-06 EA EA199900006A patent/EA199900006A1/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| YU55998A (en) | 1999-11-22 |
| PL330637A1 (en) | 1999-05-24 |
| IL126966A0 (en) | 1999-09-22 |
| TR199802496T2 (xx) | 1999-02-22 |
| ZA974978B (en) | 1998-12-07 |
| NO985695D0 (no) | 1998-12-04 |
| CZ397698A3 (cs) | 1999-05-12 |
| BR9709546A (pt) | 1999-08-10 |
| AU3233197A (en) | 1998-01-05 |
| KR20000016406A (ko) | 2000-03-25 |
| NO985695L (no) | 1999-02-04 |
| EP0914128A1 (de) | 1999-05-12 |
| EA199900006A1 (ru) | 1999-06-24 |
| JP2000511906A (ja) | 2000-09-12 |
| WO1997046241A1 (en) | 1997-12-11 |
| CN1226166A (zh) | 1999-08-18 |
| CA2256720A1 (en) | 1997-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0102482A2 (hu) | Készítmények az emberi tetű elpusztítására | |
| HUP0002196A2 (hu) | Gyógyhatású táplálékkiegészítő cukorbetegek részére | |
| IS2148B (is) | (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem COX-2 hindrar | |
| DE69527509D1 (de) | Hydrogelformulierung mit gesteuerter freisetzung | |
| AU3990797A (en) | Sustained release formulation | |
| DE60100595D1 (de) | Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson | |
| BR9912066A (pt) | Uso de um ingrediente ativo; método de tratamento de restenose; e; composição farmacêutica | |
| FR11C0017I2 (fr) | Utilisation de spinosad ou d'une formulation comprennant spinosad | |
| CY1106763T1 (el) | Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου | |
| ATE201597T1 (de) | Verabreichung von riluzol zur behandlung von neuro-aids | |
| NO951498D0 (no) | Farmasöytisk preparat for behandling av osteoporose | |
| UA35567C2 (uk) | Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату | |
| DK0998287T3 (da) | Anvendelse af levobupivacain | |
| DK0499923T3 (da) | Dentaladhæsiv | |
| HUP0104647A2 (hu) | Hatóanyagként tilidin-mezilátot tartalmazó, szabályozott hatóanyag-leadású gyógyszerkészítmény | |
| NO20000446D0 (no) | Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser | |
| DE60015508T2 (de) | C-16 ungesätigte fp-selektive prostaglandin analoge | |
| BG106548A (en) | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog | |
| HUP0003885A2 (hu) | Készítmény pangásos szívelégtelenség kezelésére | |
| ATE208200T1 (de) | Transdermales therapeutisches system (tts) zur verabreichung von testosteron | |
| GB9907571D0 (en) | Compounds | |
| DK0750616T3 (da) | Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser | |
| TR199700963T1 (xx) | Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi. | |
| WO2002096870A3 (en) | Sponge-derived terpenoids and methods of use | |
| BR0015781A (pt) | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea |